practical pharma analytical tec practical pharmaceutical analytical ...
Unlocking Pharma Growth –Emerging Markets · Unlocking Pharma Growth –Emerging Markets 1....
Transcript of Unlocking Pharma Growth –Emerging Markets · Unlocking Pharma Growth –Emerging Markets 1....
![Page 1: Unlocking Pharma Growth –Emerging Markets · Unlocking Pharma Growth –Emerging Markets 1. Indian Pharmaceutical Alliance IPA: 06/17 2. Indian Pharmaceutical Alliance Lupin Mylan](https://reader030.fdocuments.net/reader030/viewer/2022040309/5f142312ca6e5315f33a9938/html5/thumbnails/1.jpg)
Lisbon
16 June 2017
by
D G Shah
Secretary General
Indian Pharmaceutical Alliance
Joint 23rd Medicines for Europe – 20th IGBA Annual Conference
Unlocking Pharma Growth – Emerging Markets
1
![Page 2: Unlocking Pharma Growth –Emerging Markets · Unlocking Pharma Growth –Emerging Markets 1. Indian Pharmaceutical Alliance IPA: 06/17 2. Indian Pharmaceutical Alliance Lupin Mylan](https://reader030.fdocuments.net/reader030/viewer/2022040309/5f142312ca6e5315f33a9938/html5/thumbnails/2.jpg)
Indian Pharmaceutical Alliance
IPA: 06/17
2
![Page 3: Unlocking Pharma Growth –Emerging Markets · Unlocking Pharma Growth –Emerging Markets 1. Indian Pharmaceutical Alliance IPA: 06/17 2. Indian Pharmaceutical Alliance Lupin Mylan](https://reader030.fdocuments.net/reader030/viewer/2022040309/5f142312ca6e5315f33a9938/html5/thumbnails/3.jpg)
Indian Pharmaceutical Alliance
� Lupin
� Mylan
� Micro
� Natco
� Panacea Biotech
� Sun
� Torrent
� Unichem
� USV
� Wockhardt
� Alembic
� Alkem
� Cadila Healthcare
� Cadila Pharmaceuticals
� Cipla
� Dr Reddy’s
� Glenmark
� INTAS
� IPCA
� J B Chemicals
Current Members (20)
IPA: 06/17
3
![Page 4: Unlocking Pharma Growth –Emerging Markets · Unlocking Pharma Growth –Emerging Markets 1. Indian Pharmaceutical Alliance IPA: 06/17 2. Indian Pharmaceutical Alliance Lupin Mylan](https://reader030.fdocuments.net/reader030/viewer/2022040309/5f142312ca6e5315f33a9938/html5/thumbnails/4.jpg)
Indian Pharmaceutical Alliance
Contribution
*Pharmatrack MAT Mar 2016
85%
• Of total private sector investment in pharmaceutical research and development
80%• Of exports of drugs and pharmaceuticals
46%• Of price controlled drugs (NLEM)
46%• Of domestic sales
IPA: 06/17
4
![Page 5: Unlocking Pharma Growth –Emerging Markets · Unlocking Pharma Growth –Emerging Markets 1. Indian Pharmaceutical Alliance IPA: 06/17 2. Indian Pharmaceutical Alliance Lupin Mylan](https://reader030.fdocuments.net/reader030/viewer/2022040309/5f142312ca6e5315f33a9938/html5/thumbnails/5.jpg)
Indian Pharmaceutical Industry
Courtesy: McKinsey & Co.
Pharmacy of the World
IPA: 06/17
5
![Page 6: Unlocking Pharma Growth –Emerging Markets · Unlocking Pharma Growth –Emerging Markets 1. Indian Pharmaceutical Alliance IPA: 06/17 2. Indian Pharmaceutical Alliance Lupin Mylan](https://reader030.fdocuments.net/reader030/viewer/2022040309/5f142312ca6e5315f33a9938/html5/thumbnails/6.jpg)
IPM Has Shown A Robust Growth Of 12% CAGR (2012-2016) and 15% in 2015Thereafter, YoY Growth Declined to 11% in 2016 and to 9% for MAT Feb17
YOY Gwth
Source: QuintilesIMS TSA Audit TSA Dec 2016, TSA Feb 2017
Va
lue
in
crs
Indian Pharmaceutical Industry
CAGR 5 yrs
+12%
+10%+12%
+15%+11% +9%*
*For the corresponding 12-month period
IPA: 06/17
6
![Page 7: Unlocking Pharma Growth –Emerging Markets · Unlocking Pharma Growth –Emerging Markets 1. Indian Pharmaceutical Alliance IPA: 06/17 2. Indian Pharmaceutical Alliance Lupin Mylan](https://reader030.fdocuments.net/reader030/viewer/2022040309/5f142312ca6e5315f33a9938/html5/thumbnails/7.jpg)
McKinsey View of Indian Pharmaceutical Industry
Courtesy: McKinsey & Co.
1 Industry has grown to become 8th largest country globally and continues to have one of the highest growth rates
IPA: 06/17
7
![Page 8: Unlocking Pharma Growth –Emerging Markets · Unlocking Pharma Growth –Emerging Markets 1. Indian Pharmaceutical Alliance IPA: 06/17 2. Indian Pharmaceutical Alliance Lupin Mylan](https://reader030.fdocuments.net/reader030/viewer/2022040309/5f142312ca6e5315f33a9938/html5/thumbnails/8.jpg)
McKinsey View of Indian Pharmaceutical Industry
Courtesy: McKinsey & Co.
IPA: 06/17
8
![Page 9: Unlocking Pharma Growth –Emerging Markets · Unlocking Pharma Growth –Emerging Markets 1. Indian Pharmaceutical Alliance IPA: 06/17 2. Indian Pharmaceutical Alliance Lupin Mylan](https://reader030.fdocuments.net/reader030/viewer/2022040309/5f142312ca6e5315f33a9938/html5/thumbnails/9.jpg)
Drug Regulatory Regime
� FDC Ban
� Generic Prescribing
� Capability Building
Key Issues
1
Aligning With Global Agencies
IPA: 06/17
9
![Page 10: Unlocking Pharma Growth –Emerging Markets · Unlocking Pharma Growth –Emerging Markets 1. Indian Pharmaceutical Alliance IPA: 06/17 2. Indian Pharmaceutical Alliance Lupin Mylan](https://reader030.fdocuments.net/reader030/viewer/2022040309/5f142312ca6e5315f33a9938/html5/thumbnails/10.jpg)
Pricing Policy2
Implementation Issues
Tilting Delicate Balance Between Access and Availability
� Tweaking Definition of Brand to Inflict Deeper Price Cuts
� Denying/Delaying Price Approvals
� Retrospective Pricing: Burden of Compliance
� Frequent Price Revisions
IPA: 06/17
10
![Page 11: Unlocking Pharma Growth –Emerging Markets · Unlocking Pharma Growth –Emerging Markets 1. Indian Pharmaceutical Alliance IPA: 06/17 2. Indian Pharmaceutical Alliance Lupin Mylan](https://reader030.fdocuments.net/reader030/viewer/2022040309/5f142312ca6e5315f33a9938/html5/thumbnails/11.jpg)
Innovation 3
Courtesy: McKinsey & Co.
IPA: 06/17
11